XML 59 R35.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies - Narrative (Details) (USD $)
3 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2014
segment
Dec. 31, 2013
Dec. 31, 2012
May 16, 2014
May 31, 2014
Dec. 31, 2014
Dec. 31, 2009
Accounting Policies [Abstract]                      
Letter of credit                     $ 200,000us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
Restricted cash 0us-gaap_RestrictedCashAndCashEquivalentsNoncurrent       0us-gaap_RestrictedCashAndCashEquivalentsNoncurrent 200,000us-gaap_RestrictedCashAndCashEquivalentsNoncurrent       0us-gaap_RestrictedCashAndCashEquivalentsNoncurrent  
Allowance for doubtful accounts 102,000us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent       102,000us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent 18,000us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent       102,000us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent  
Payment discounts         59,000us-gaap_SalesDiscountsGoods 118,000us-gaap_SalesDiscountsGoods          
Concentration Risk [Line Items]                      
Period to accept returned unused product after product expiration         1 year            
Impairment of long-lived assets 0us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf 0us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf 838,000us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf 0us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf 838,000us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf 0us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf 0us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf        
Advertising expense         6,062,000us-gaap_AdvertisingExpense 1,330,000us-gaap_AdvertisingExpense 1,333,000us-gaap_AdvertisingExpense        
Foreign currency gains (losses)         (145,000)us-gaap_ForeignCurrencyTransactionGainLossBeforeTax (95,000)us-gaap_ForeignCurrencyTransactionGainLossBeforeTax (68,000)us-gaap_ForeignCurrencyTransactionGainLossBeforeTax        
Number of operating segments         1us-gaap_NumberOfOperatingSegments            
Sales Revenue, Product Line [Member]                      
Concentration Risk [Line Items]                      
Number of customers         3zgnx_ConcentrationRiskNumberofCustomers
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueProductLineMember
           
Accounts Receivable [Member]                      
Concentration Risk [Line Items]                      
Number of customers         3zgnx_ConcentrationRiskNumberofCustomers
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_AccountsReceivableMember
           
Pharmaceutical Distributor, Customer One [Member] | Sales Revenue, Product Line [Member]                      
Concentration Risk [Line Items]                      
Concentration risk         33.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueProductLineMember
/ us-gaap_MajorCustomersAxis
= zgnx_CustomerOneMember
           
Pharmaceutical Distributor, Customer Two [Member] | Sales Revenue, Product Line [Member]                      
Concentration Risk [Line Items]                      
Concentration risk         32.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueProductLineMember
/ us-gaap_MajorCustomersAxis
= zgnx_CustomerTwoMember
           
Pharmaceutical Distributor, Customer Three [Member] | Sales Revenue, Product Line [Member]                      
Concentration Risk [Line Items]                      
Concentration risk         23.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueProductLineMember
/ us-gaap_MajorCustomersAxis
= zgnx_CustomerThreeMember
           
Pharmaceutical Distributor, Customer One, Two and Three [Member] | Accounts Receivable [Member]                      
Concentration Risk [Line Items]                      
Concentration risk         79.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_AccountsReceivableMember
/ us-gaap_MajorCustomersAxis
= zgnx_CustomerOneTwoandThreeMember
           
Minimum [Member]                      
Concentration Risk [Line Items]                      
Rebate repayment period         2 months            
Maximum [Member]                      
Concentration Risk [Line Items]                      
Rebate repayment period         3 months            
Sumavel DosePro [Member]                      
Concentration Risk [Line Items]                      
Cost of goods sold mark-up, in percent               2.50%zgnx_DiscontinuedOperationContinuationofActivitieswithDiscontinuedOperationafterDisposalCostofGoodsSoldMarkupPercent
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= zgnx_SumavelDoseproMember
2.50%zgnx_DiscontinuedOperationContinuationofActivitieswithDiscontinuedOperationafterDisposalCostofGoodsSoldMarkupPercent
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= zgnx_SumavelDoseproMember
   
Restricted cash and cash equivalents 8,500,000us-gaap_RestrictedCashAndCashEquivalents
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= zgnx_SumavelDoseproMember
      8,500,000us-gaap_RestrictedCashAndCashEquivalents
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= zgnx_SumavelDoseproMember
        8,500,000us-gaap_RestrictedCashAndCashEquivalents
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= zgnx_SumavelDoseproMember
 
Potential indemnification period               12 months 12 months    
Contract Manufacturing [Member] | Sales Revenue, Product Line [Member]                      
Concentration Risk [Line Items]                      
Number of customers         1zgnx_ConcentrationRiskNumberofCustomers
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueProductLineMember
/ us-gaap_ProductOrServiceAxis
= zgnx_ContractManufacturingMember
           
Sumavel DosePro [Member]                      
Concentration Risk [Line Items]                      
Period to accept returned unused product after product expiration         1 year            
Number of subassemblies         2zgnx_NumberofSubassemblies
/ us-gaap_ProductOrServiceAxis
= zgnx_SumavelDoseproMember
           
Endo Ventures Supply Agreement [Member] | Minimum [Member]                      
Concentration Risk [Line Items]                      
Term of agreement                   8 years  
Cost of Sales [Member] | Zohydro ER [Member]                      
Concentration Risk [Line Items]                      
Inventory adjustments         5,769,000us-gaap_InventoryWriteDown
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_CostOfSalesMember
/ us-gaap_ProductOrServiceAxis
= zgnx_ZohydroERMember
           
Cost of Goods, Total [Member] | Zohydro ER [Member]                      
Concentration Risk [Line Items]                      
Non-cancellable purchase commitment adjustment         $ 2,594,000us-gaap_ProductionRelatedImpairmentsOrCharges
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_CostOfGoodsTotalMember
/ us-gaap_ProductOrServiceAxis
= zgnx_ZohydroERMember